|Videos|January 18, 2023

The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME